Tags: Royalty Pharma
Elan Rejects Royalty Pharma Takeover Bid
Elan rejects takeover bid of Royalty Pharma, saying it grossly undervalued the firm. The board of directors of Elan, the Irish pharmaceutical company has unanimously rejected the formal bid from Royalty Pharma.
Johnson and Johnson Divestment Clouds Takeover Bid
Johnson and Johnson accounted for 92.3% of shares bought back, complicating matters for the Royalty Pharma takeover of Elan Pharmaceuticals.
Elan Shareholders Approve Buyback Plan
Elan shareholders approve buyback plan to avert takeover bid from Royalty Pharma. Shareholders of Irish drug maker, Elan, approved a US$1 billion or GBP651 million share buyback approval.
Royalty Pharma Offers US$6.6Bln Offer for Elan
Royalty Pharma offers US$11 per Elan share. While Elan is in the process of selling its fifty percent share in the successful multiple scelerosis drug Tysabri with its US partner Biogen Idec, here comes American investment firm Royalty Pharma offering US6.
